Filter content

A Toronto-based company is looking to have an impact on the treatment of opioid addiction by exploring the potential of psychedelics, an area of study that to this point has seen more intense activity in the mental health field. Mind Medicine Inc. (Mindmed) announced this week that it has acquired…

Methamphetamine's resurgence has refocused attention to the needs of a group of users for whom meth use and compulsive sexual behavior become intertwined. At this November's Cocaine, Meth & Stimulant Summit in Miami, prominent interventionist and Breathe Life Healing Centers founder Brad Lamm,…

As is the case with traditional cigarettes, use of electronic cigarettes is associated with sleep problems and compromised overall sleep health, a study involving college students finds.

Maladaptive coping strategies in patients frequently are a result of the traumatic events experienced by previous generations of patients’ families—a phenomenon known as either intergenerational trauma or transgenerational trauma. It’s a challenge that requires practitioners to dig deeper in their…

By Julie Steenhuysen CHICAGO—U.S. health officials on Thursday cut the number of lung illnesses linked to e-cigarettes and vaping products under investigation to 380 as states began assessing patients based on a narrower case definition issued late last month by the Centers for Disease Control and…

Newly published research highlights serious medical outcomes associated with misuse of prescription stimulants, with administration of the drugs by injection associated with the most adverse effects.

Michigan Gov. Gretchen Whitmer's executive order earlier this month to ban all flavored e-cigarette products outside of tobacco-flavored e-cigs has turned out to be a preview of far-reaching action at the federal level. The Trump administration announced on Wednesday that it will take steps to…

OxyContin maker Purdue Pharma LP reached a tentative agreement with some plaintiffs to resolve widespread litigation over its alleged role in fueling the U.S. opioid crisis, people familiar with the matter said.

OxyContin maker Purdue Pharma LP is nearing a multibillion-dollar partial agreement aimed at settling thousands of lawsuits over its alleged role in the U.S. opioid crisis, Reuters reported on Wednesday, citing people familiar with the matter.

Taking the term “meeting patients where they're at” to another level, a leading provider of opioid use disorder (OUD) treatment in Rhode Island is using a 37-foot mobile medical unit to visit underserved areas of the state with high numbers of overdose and HIV cases.